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Abstract The turnover of cellular proteins is a highly orga-
nized process that involves spatially and temporally regulated
degradation by the ubiquitin/proteasome system. It is generally
acknowledged that the speci¢city of the process is determined by
constitutive or conditional protein domains, the degradation sig-
nals, that target the substrate for proteasomal degradation. In
this review, we discuss a new type of regulatory domain: the
stabilization signal. A model is proposed according to which
protein half-lives are determined by the interplay of counteract-
ing degradation and stabilization signals. " 2002 Federation
of European Biochemical Societies. Published by Elsevier Sci-
ence B.V. All rights reserved.
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1. Introduction
It is not without good reasons that molecular biologists
scrutinize novel proteins for functional domains in a ¢rst at-
tempt to understand their contribution to the physiology of
the cell. The presence of speci¢c modular domains or motifs
may give hints on protein localization, enzymatic activity,
posttranslational modi¢cations and interaction with other
proteins. A clear illustration of the predictive power of do-
mains can be found in the large variety of proteins involved in
the ubiquitin/proteasome system. The presence of speci¢c do-
mains can reveal important functional features of these pro-
teins such as their involvement in ubiquitination, character-
ized by the presence of HECT domains, RING ¢ngers or
U-boxes [1], their capacity to function as adaptor proteins,
characterized by the presence of, for example, F-boxes [2],
or their capacity to bind ubiquitin through UBA and UIM
domains [3]. Not only the activity of proteins but also their
lifespan is determined by the presence of speci¢c domains or
motifs. Of key importance are in this respect the degradation
signals that target proteins for proteasomal degradation. In
this minireview, we discuss recently published studies that
suggest the presence of a second type of regulator of protein
turnover, the stabilization signal, that counteracts the activity
of degradation signals.
2. Degradation signals
The insight that the turnover of intracellular protein is a
highly organized and energy-demanding process executed by
the ubiquitin/proteasome system emerged only two decades
ago. Since then, the combined e¡ort of many researchers
has unravealed a proteolytic machinery of unexpected com-
plexity. At the basis of the proteolytic event lies a relatively
simple two-step process: (1) proteins are provided with a deg-
radation tag, a polyubiquitin tree consisting of multiple ubiq-
uitin monomers, which is covalently linked by its carboxy
terminus to the amino group of a lysine residue within the
substrate [4] ; (2) the polyubiquitinated substrate is recognized
by a large proteolytic complex, the proteasome, which unfolds
and progressively degrades the protein in small peptides [5].
These two core events are subject to a multitude of regulatory
interactions that determine the selectivity and e⁄ciency of
ubiquitin/proteasome-dependent proteolysis.
A major determinant for protein half-life is the presence of
degradation signals [6]. The ¢rst identi¢ed degradation signal,
which regulates protein turnover by recognizing their N-ter-
minal amino acid residue, was described shortly after the dis-
covery of the ubiquitin/proteasome system [7]. This so-called
N-end rule degron was soon followed by other well-de¢ned
degradation signals such as the ubiquitin fusion degradation
(UFD) signal, the PEST sequence and the destruction box [6].
Some degradation signals were shown to be constitutive while
others behave as conditional signals regulated by phosphory-
lation/dephosphorylation [8]. Both modular domains as well
as small peptide sequences have been shown to act degrada-
tion signals. Regardless of the type of signal, each of these
domains accelerates the turnover of proteins by recruiting an
ubiquitin ligase, the speci¢c E3 that conjugates a polyubiqui-
tin tree to the substrate [1,4]. The e⁄cacy of ubiquitin ligase
recruitment is a major determinant of the ubiquitination rate.
In several cases it has been shown that the degradation signal
can be transferred to a di¡erent protein, which then becomes
a substrate for the relevant ubiquitin ligase.
3. Stabilization signals
Recent evidence suggests that, in addition to degradation
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signals, proteins may also contain stabilization signals that act
as positive regulators of protein half-life by delaying or block-
ing their degradation. In order to be classi¢ed as stabilization
signals, these structures should share at least some of the
properties of modular domains such as: (a) deletion of the
domain from the wild-type protein should abrogate the phe-
notype associated with the domain and (b) introduction of the
domain in a new host protein should results in a gain-of-
function. When translated to the stabilization domain this
means that their removal should results in accelerated turn-
over of the protein, while introduction of the domain in an
unrelated proteasome substrate should slow down the turn-
over of the host protein (Fig. 1).
It is noteworthy that while degradation signals appear to
act primarily by regulating the rate of ubiquitination, several
events are potential targets for stabilization signals. For ex-
Fig. 1. Identi¢cation of stabilization signals. Stabilization signals can be revealed by a two-step experimental approach. Deletion of the sus-
pected stabilization domain (STA) from the protein should result in accelerated degradation. Degradation should be accomplished through an
endogenous degradation signal (DEG) that is also active in the wild-type protein and not through introduction of new degradation signals (for
example, due to misfolding). Insertion of the stabilization signal into an unrelated proteasome substrate carrying a di¡erent degradation signal
(DEG*) should delay or block degradation of the new host protein.
Fig. 2. Events in the ubiquitin/proteasome system that can be modi¢ed by stabilization signals. Substrates are targeted for proteasomal degra-
dation by conjugation of a polyubiquitin tree through the concerted action of ubiquitin activase (E1), ubiquitin conjugases (E2) and ubiquitin
ligases (E3). The polyubiquitinated substrate is bound to the proteasome and progressively degraded into small peptides. Stabilization signals
can modify several discrete steps of the process including: (1) accelerate deubiquitination, (2) modify the kinetics of substrate^proteasome inter-
action or (3) block the unfolding of the substrate. DUB, deubiquitination enzyme.
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ample, proteasomal degradation may be negatively regulated
by accelerating the deubiquitination of substrates, by modify-
ing the substrate^proteasome interaction or by hampering
substrate unfolding. Hence, it may be possible to distinguish
multiple classes of stabilization signals a¡ecting di¡erent
stages of the ubiquitin/proteasome system (Fig. 2). Three
classes of stabilization signals that are supported by available
experimental evidence will be discusses in the next section.
Given the complexity of the ubiquitin/proteasome system, it
is unlikely that these three classes will cover the full spectrum
of possible stabilization signals.
3.1. Repetitive and low-complexity stabilization signals
The small proteolytic fragments that are produced by the
proteasome are the major source of peptides that are pre-
sented at the cell surface by major histocompatibility class I
molecules [9]. If the presented peptide is derived from a for-
eign or mutant protein this is likely to trigger speci¢c cyto-
toxic T cells that will eliminate the altered cells. Viruses and
other intracellular pathogens have evolved ways to interfere
with antigen presentation [10]. The Epstein^Barr virus nuclear
antigen 1 (EBNA1) contains a repetitive sequence that blocks
proteasomal degradation [11,12]. The repetitive sequence
varies in length in di¡erent viral isolates and consists exclu-
sively of Gly and Ala residues. Deletion of the Gly-Ala repeat
(GAr) restored proteasomal degradation of EBNA1 [12],
while insertion of the GAr in an array of other proteasome
substrates resulted in partial or full blockade of proteasomal
degradation [13^15]. Moreover, the EBNA1 homologues en-
coded by related viruses that infect baboons and rhesus ma-
caques contain similar repetitive sequences composed of Gly,
Ala and Ser residues [16]. Although these repeats do not fully
block antigen presentation, they do slow down the proteaso-
mal degradation of the EBNA1 homologues. The mode of
action of the GAr is not fully understood but several ¢ndings
point to interference with a late step in the proteolytic process,
possibly downstream of the interaction of ubiquitinated sub-
strates with the proteasome. Of note, GAr containing proteins
are ubiquitinatinated in vivo and can still interact with one of
the proteasome subunits responsible polyubiquitin binding
[15].
Interestingly, low-complexity sequences are required for
partial processing of a few proteasome substrates. Presence
of these sequences causes selective degradation of the part
of the protein situated C-terminal to the sequence while the
N-terminal domain and the low-complexity sequence itself are
protected from degradation. The ¢rst example of this type of
regulator was found in the p105 precursor of the transcription
factor NF-UB which contains a Gly rich region (GRR) that is
required for processing to the active p50 [17]. This sequence
shows some similarity to the GAr and contains Ala residues
that are crucial for its activity as a processing signal [18].
Importantly, it was shown that the GRR is not only required
for processing of p105 but also prolongs the half-life of the
resulting p50 [18]. Attempts to transfer this processing signal
to other proteins have failed so far suggesting that additional
peptide motifs may be required. More recently, it has been
shown that two transmembrane transcription factors involved
in the lipid metabolism of budding yeast, Spt23p and Mga2p,
require processing in order to be released from the membrane
[19]. Spt23p and Mga2 contain low-complexity domains at
approximately the same position as the GRR and it has
been postulated, though not proven, that these domains are
functional analogues to the p105 GRR [20].
While additional studies are required to elucidate whether
the viral GAr and the processing signals display a similar
mode of action, the evidence for each of these low-complexity
sequences suggests that they a¡ect events downstream of the
interaction with the proteasome providing some support for a
shared inhibitory mechanism.
3.2. Conformational stabilization signals
Unfolding of the substrate by the regulatory subunit of the
proteasome is an important step of ubiquitin/proteasome-de-
pendent proteolysis. In two independent studies with designed
proteasome substrates, degradation was inhibited by the in-
troduction of tightly folded domains that resist the unfoldase
activity of the proteasome [21,22]. In the ¢rst study, the in-
troduction of two domains that fold upon binding their spe-
ci¢c ligands caused a ligand-dependent stabilization of a pro-
teasome substrate [21]. More recently, Navon and Goldberg
have shown that the degradation of a proteasomal substrate
was abrogated by linkage of a large biotin^avidin complex
[22]. Interestingly in both studies a strong positional e¡ect
was observed suggesting that the proteasome initiates unfold-
ing from a speci¢c location within the protein. Furthermore,
in the latter study the unfolding-resistant substrate functioned
as general inhibitor of the ubiquitin/proteasome system. The
biological signi¢cance of these observations based on designed
substrates is supported by the study by Lee and co-workers
indicating that, in addition to the GRR, protein folding may
be important for the processing of p105 [21].
Increasing evidence implicates protein folding as a key de-
terminant in the pathogenesis of neurodegenerative disorders
that are caused by expansions of polyglutamine repeats in
various proteins [23]. The expanded polyglutamine repeats
were shown to slow down proteasomal degradation [24].
The characteristic formation of aggregates may partly explain
this resistance as the tight complexes may hinder the unfold-
ing of the proteins by the proteasome. Indeed, we have re-
cently obtained evidence that the stabilizing e¡ect of the ex-
panded polyglutamine repeats is related to their capacity to
form aggregates. While soluble polyglutamine containing sub-
strates were rapidly degraded by the proteasome, their aggre-
gated forms resisted proteasomal degradation [43]. Interest-
ingly, similar to the designed unfolding-resistant substrate
also the polyglutamine aggregates can cause impairment of
the ubiquitin/proteasome system [25].
It is also noteworthy that an aberrant ubiquitin found in
a¡ected neurons of Alzheimer’s patients is targeted for pro-
teasomal degradation through a UFD signal but, when over-
expressed, it is stable and functions as a general inhibitor of
the ubiquitin/proteasome system [26,27]. Thus, the aberrant
ubiquitin may act by challenging the unfolding or transloca-
tion activity of the proteasome.
3.3. Deubiquitination stabilization signals
The identi¢cation and characterization of enzymes that rec-
ognize and ubiquitinate the substrates has been a major focus
in the ubiquitin/proteasome ¢eld [1]. While the pivotal role of
ubiquitinating enzymes is undisputed, the interest in their en-
zymatic opposites, the deubiquitinating enzymes, is rapidly
emerging [28]. The presence of a large number of deubiquiti-
nating enzymes that share little sequence similarities suggests
FEBS 26478 17-9-02 Cyaan Magenta Geel Zwart
N.P. Dantuma, M.G. Masucci/FEBS Letters 529 (2002) 22^2624
a yet largely unexplored substrate speci¢city of this class of
proteins [29].
Protein domains that recruit deubiquitinating enzymes and
delay thereby the ubiquitin-dependent turnover of substrates
are the most striking counterparts of the degradation signals.
Surprisingly the knowledge about substrates of the large fam-
ily of deubiquitinating enzymes is very limited but recent stud-
ies shed some light on this important issue. The human ho-
mologue of the Drosophila deubiquitination enzyme fat
facets, Fam, was shown to stabilize two di¡erent substrates,
the ras-target AF-6 [30] and L-catenin [31]. Moreover, Li and
co-workers have recently reported that the deubiquitination
enzyme USP7 can stabilize the tumor suppressor p53 through
deubiquitination [32]. While each of these substrates was
shown to directly interact with the relevant deubiquitinating
enzyme, only for the two Fam substrates the interaction do-
main has been partially mapped and no attempts have been
made to assess the transferability of the interacting domains
to other substrates [30,31].
4. Why would substrates need stabilization signals?
A legitimate question is why proteins should carry two
counteracting signals in order to regulate their proteasomal
turnover when a delay of proteasomal degradation could be
easily achieved by modi¢cation of the degradation signal, re-
sulting in sub-optimal recruitment of ubiquitin ligases. One
obvious answer is that the presence of two counteracting sig-
nals adds new opportunities of regulation. This is clearly illus-
trated by the processing of precursor proteins where the deg-
radation signal induces proteolysis of a fragment of the
protein while the remaining part escapes degradation. Hence,
a processing signal should contain both a degradation and a
stabilization signal. In contrast to the viral repeats that block
proteasomal degradation tout-court, the nature of protein
processing requires a stabilization signal that is only active
once the degradation of the substrate is initiated.
An interesting possibility is that the spatial or temporal
degradation of certain proteins may be regulated by condi-
tional stabilization signals. Thus, opposite to what has been
observed for many proteasome substrates, such proteins may
be targeted for degradation by default and this fate can be
overruled by activation of a conditional stabilization signal.
An example may be the regulation of protein turnover by the
levels of the speci¢c deubiquitination enzymes. Indeed, the
expression of deubiquitination enzymes changes dramatically
during senescence [33] or upon oncogene activation [34], but
the speci¢c substrates of these enzymes remain to be identi-
¢ed. Other regulatory signals could be functional analogous to
the conformational stabilization signal described by Lee and
co-workers, which resists the unfoldase activity of the protea-
some only after binding of its speci¢c ligand [21]. One tanta-
lizing observation in this respect is the regulation of the tran-
scriptional regulator Met4 in budding yeast. The level of
methionine in the culture medium controls the degradation
of Met4 [35]. Yet, while addition of methionine results in
ubiquitination of Met4, only in minimal medium this is fol-
lowed by proteasomal degradation whereas in rich medium
the ubiquitinated Met4 is stable but has an altered promotor
speci¢city [36,37]. Although alternative explanations cannot
be excluded, it is tempting to speculate that Met4 may carry
a stabilization signal that is active depending on the nutrient
status of the medium analogous to the ligand-dependent sta-
bilization signals in the designed substrates.
Although ubiquitination is regarded as a major determinant
of intracellular protein turnover, it has become clear that
ubiquitin modi¢cation is also crucial for many other cellular
processes such as membrane tra⁄cking [38], DNA repair [39],
and protein activation [40]. These di¡erent activities of ubiq-
uitinated substrates are usually permitted by the conjugation
of polyubiquitin trees via Lys residues di¡erent form the ca-
nonical Lys48, that mediates proteasomal degradation. How-
ever, the presence of strong stabilization signals could allow
Lys48 polyubiquitination without proteolysis. These stable
polyubiquitinated substrates may be targeted to the protea-
some and mediate the recruitment of co-factors that regulate
the proteolytic machinery or facilitate non-proteolytic activ-
ities of the proteasome, such as the recently discovered role of
the 19S regulatory subunit in DNA repair [41].
5. Concluding remarks
While a few viral repeats clearly ful¢l the criteria for func-
tional domains with stabilizing e¡ects, the presence of other
classes of stabilization signals is still a matter of speculation.
Yet, the identi¢cation and characterization of this type of
regulatory sequences is a major challenge for the future. A
strong focus will be on the pathogenesis of conformational
diseases characterized by the accumulation of misfolded pro-
teins that are usually rapidly destroyed by proteasomal deg-
radation [42]. A key question is why the cells fail to clear the
toxic and aggregation-prone proteins [23]. If stabilization sig-
nals are involved, overriding their e¡ect or targeting the toxic
proteins before conditional stabilization signals are activated
could provide a new therapeutic approach. The immune eva-
sion strategy of EBV based on the protective e¡ect of the GAr
illustrates another interesting opportunity. Stabilization sig-
nals may turn into powerful tools for the generation of non-
immunogenic proteins or stable variants of proteasome sub-
strate for gene therapeutic applications.
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